Biohaven Ltd., a clinical-stage biopharmaceutical company based in New Haven has announced the pricing of a public offering expected to raise $175 million. A leader in neuroscience, immunology, and rare disease therapeutics, Biohaven is expanding its efforts to develop life-changing health solutions for patients across Connecticut and beyond.

The offering includes 23,333,334 shares priced at $7.50 each. Underwriters have also been granted a 30-day option to purchase up to 3.5 million additional shares. The offering is expected to close on November 13, 2025, subject to customary conditions.  Biohaven intends to use the net proceeds received from the offering for general corporate purposes.

Founded and headquartered in New Haven, Biohaven is known for its deep pipeline of investigational therapies targeting neurological, autoimmune, and neuropsychiatric conditions. The company has earned national recognition for its science-driven approach and partnerships with leading research institutions. In recent years, it has delivered FDA-approved therapies for migraine and advanced new treatments for epilepsy, anxiety, and depression.

With the Connecticut life sciences sector continuing to grow, Biohaven’s fundraising success further cements its leadership in health innovation and economic impact in the region.